FIELD: pharmaceuticals.
SUBSTANCE: invention relates to new compounds of Formula (I), to pharmaceutical compositions containing the specified compounds, and to the use of the compounds in the treatment of diseases mediated by FGFR activity, such as cancer.
EFFECT: invention can be used in the treatment of diseases mediated by FGFR activity, such as cancer.
20 cl, 3 tbl, 4 ex
(I)
Title | Year | Author | Number |
---|---|---|---|
NEW COMPOUNDS | 2016 |
|
RU2747645C2 |
PTERIDINES AS FGFR INHIBITORS | 2013 |
|
RU2702906C2 |
QUINAZOLINONE DERIVATIVES APPLICABLE AS MODULATORS OF FGFR KINASE | 2014 |
|
RU2701517C2 |
SUBSTITUTED QUINAZINE DERIVATIVES AS FGFR-KINASE INHIBITORS FOR TREATMENT OF CANCER | 2011 |
|
RU2602233C2 |
COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
NEW COMPOUNDS | 2013 |
|
RU2654857C2 |
COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806625C2 |
DERIVATIVES OF 1,5- AND 1,7-NAPHTHYRIDINE USEFUL IN TREATMENT OF FGFR-MEDIATED DISEASES | 2012 |
|
RU2629194C2 |
NEW QUINOLINE COMPOUNDS | 2018 |
|
RU2810113C2 |
COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806751C2 |
Authors
Dates
2021-05-11—Published
2016-09-22—Filed